Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Blesl, A; Krones, E; Pollheimer, MJ; Haybaeck, J; Wiesspeiner, U; Lipp, RW; Kump, P.
Downgrading of a G3 Neuroendocrine Tumor to a G2 Tumor: Can First-Line Cytotoxic Chemotherapy Change the Tumor Biology?
Case Rep Oncol. 2018; 10(3):1121-1126
Doi: 10.1159/000484473
(- Case Report)
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Blesl Andreas
- Kump Patrizia
- Co-Autor*innen der Med Uni Graz
- Haybäck Johannes
- Lipp Rainer
- Pollheimer Marion
- Tatscher Elisabeth
- Wießpeiner Ulrike Josefine
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The antiproliferative treatment options for neuroendocrine tumors (NET)/neuroendocrine carcinomas of the gastrointestinal tract critically depend on the proliferation rate, evaluated by immunohistochemical staining for Ki-67. According to their grading, tumors are treated with somatostatin analogs, mTOR inhibitors, or cytotoxic substances. This case illustrates downgrading of a primarily highly proliferative NET achieved by a variation of cytotoxic chemotherapy regimens, followed by a combination therapy using everolimus together with lanreotide. The latter medication might lead to a good clinical response as far as tumor growth is concerned.
- Find related publications in this database (Keywords)
- Neuroendocrine tumor
- Chemotherapy
- Liver biopsy
- mTor
- Somatostatin